This is especially relevant for endpoints such as viability, migration, and tube formation, which can be sensitive to culture conditions and reagent variability
Alternatively, either one would be a great choice
News Release: Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
Participants in this phase 3 trial saw remarkable outcomes at 80 weeks: a weight loss averaging 28.3% on the 12 mg dose
B-vitamin sharing promotes stability of gut microbial communities
Less effective blood sugar management, for those using semaglutide for glycemic control, is another performance indicator